CSL Limited (CSL)
BUY

CSL - Stock Update

 12 Apr 2022
Sector: Health Care

Event spotlight

A potential catalyst for CSL over the next 3-6 months could be wider publicity of the Vifor deal. CSL hasn’t said much about the Vifor deal given it settles in the middle of the year. Once settlement occurs there is the possibility for an elevated market reaction due to the release of further information.

CSL share price seems to have seen some indigestion within the market given the recent equity raising to pay for the Vifor acquisition ($6.3bn institution placement + $750m SPP) although given settlement is due to occur in the middle of the year there could be a clearer path for CSL once more information is available.

CSL price chart and volume distribution since the Vifor deal was announced

CSL price chart and volume distribution since the Vifor deal was announced

Source: Bloomberg

View the latest Research Report

Company overview

CSL is a biotech company which provides leading technology & services globally with notable products and services being vaccinations and plasma collection.

CSL is positioned to benefit from the newly FDA approved Rika apheresis device which it plans to use to switch its current plasma collection fleet. The new fleet as well as the settlement of the Vifor deal supports our investment thesis of a buy rating for CSL.

Disclaimers and Disclosures

Issuer

The information and opinions contained within Sandstone Insights Research were prepared by MST Financial Services Pty Ltd (ABN 54 617 475 180, AFSL 500557) ("MST").

Reliance

Whilst MST make every effort to use reliable, comprehensive information in the construction of its reports, MST make no representation, warranty or undertaking of the accuracy, timeliness or completeness of information in this report. Save for any statutory liability that cannot be excluded, MST and MST employees, representative and agents shall not be liable (whether in negligence or otherwise) for any error or inaccuracy in, or omission from, this advice or any resulting loss suffered by the recipient or any other person.

General Advice

Any advice contained within Sandstone Insights Research is general advice only and has been prepared without taking into account any person’s objectives, financial situation or needs. Any person, before acting on any advice contained within Sandstone Insights Research, should first consider consulting with a financial adviser to assess whether that advice is appropriate for their objectives, financial situation and needs. 

General Disclosures

This report should be read in conjunction with MST Disclaimers and Disclosures and is published in accordance with MST Conflict Management Policy which are available on the MST website: https://www.sandstoneinsights.com.au. 

Currency of Research

The recommendations made in a Sandstone Insights Research report are current as of the publication date. If you are reading a report materially after publication, it is likely that circumstances will have changed and at least some aspects of the analysis may no longer hold.

Access and Use

Any access to or use of Sandstone Insights Research is subject to the Terms of Use. By accessing or using Sandstone Insights Research you hereby agree to be bound by our Terms and Conditions and hereby liable for any monies due in payment of accessing this service. In addition you consent to us collecting and using your personal data (including cookies) in accordance with MST Privacy Policy, including for the purpose of a) setting your preferences and b) collecting readership data so MST may deliver an improved and personalised service to you. If you do not agree to MST Terms of Use and/or if you do not wish to consent to MST use of your personal data, please do not access this service.

Equities Research Methodology

Please click here for information about MST equities research methodology.